Beijing Tongren Hospital, Capital Medical University, Beijing, China.
Clin Otolaryngol. 2021 Sep;46(5):1013-1020. doi: 10.1111/coa.13772. Epub 2021 Apr 21.
The use of immunotherapy to treat recurrent/metastatic squamous cell carcinoma of the head and neck has become a popular research topic in recent years, and many clinical trials have been carried out.
To systematically evaluate the efficacy and safety of PD-1/PD-L1 inhibitors in the treatment of recurrent/metastatic head and neck squamous cell carcinoma.
We searched PubMed, Embase, Cochrane Library and other databases up to 1 November 2019 for publications reporting the use of PD-1/PD-L1 inhibitors in the treatment of squamous cell carcinoma of the head and neck. Revman 5.0 was used for combination analysis, and the overall survival (OS), progression-free survival (PFS), overall response rate (ORR) and adverse events were determined.
Five articles were included. Compared with other treatment methods, this meta-analysis showed that treatment with PD-1/PD-L1 inhibitors can significantly improve OS (P < .0001), but there was no significant improvement in PFS or ORR. The risk of anaemia and nausea was significantly reduced by treatment with PD-1/PD-L1 inhibitors.
Treatment with PD-1/PD-L1 inhibitors alone can improve the overall survival rate for recurrent/metastatic squamous cell carcinoma of the head and neck but there is no obvious advantage in other aspects and adverse events.
免疫疗法治疗复发性/转移性头颈部鳞状细胞癌已成为近年来的热门研究课题，开展了许多临床试验。
系统评价 PD-1/PD-L1 抑制剂治疗复发性/转移性头颈部鳞状细胞癌的疗效和安全性。
我们检索了 PubMed、Embase、Cochrane Library 等数据库，截至 2019 年 11 月 1 日，检索关于 PD-1/PD-L1 抑制剂治疗头颈部鳞状细胞癌的文献。使用 Revman 5.0 进行合并分析，确定总生存期（OS）、无进展生存期（PFS）、总缓解率（ORR）和不良事件。
共纳入 5 篇文章。与其他治疗方法相比，该荟萃分析表明，PD-1/PD-L1 抑制剂治疗可显著提高 OS（P<.0001），但 PFS 或 ORR 无显著改善。PD-1/PD-L1 抑制剂治疗可显著降低贫血和恶心的风险。
PD-1/PD-L1 抑制剂单独治疗可提高复发性/转移性头颈部鳞状细胞癌的总生存率，但在其他方面和不良事件方面没有明显优势。
